Smart bomb drug trial targets tough cancers with genetic flaw
NCT ID NCT04439110
Summary
This trial is testing a targeted drug called ado-trastuzumab emtansine for patients with advanced cancers that have a specific genetic change called HER2 amplification. The drug is designed to find cancer cells with the HER2 marker and deliver chemotherapy directly to them. The study aims to see if this approach can shrink tumors or stop their growth in patients whose cancers have not responded to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.